Uterus smooth muscle cell contraction pathway

The uterus smooth muscle cell contraction pathway comprises cellular mechanisms involving the myometrium (uterine muscle layer), most notably the influx of calcium via L-type calcium channels, activation of the oxytocin receptor, release of calcium from the sarcoplasmic reticulum, and downstream engagement of calmodulin and myosin light chain kinase. These events result in phosphorylation of myosin, cross-bridge cycling with actin, and forceful uterine contractions. The pathway is essential for labor and other uterine contractile functions, with its balance (relaxation vs. contraction) governed by hormonal and electrical inputs. This pathway’s dysfunction is implicated in preterm labor, infertility, and various uterine disorders. It is a physiological process rather than a discrete molecular target for therapeutics. This entity describes a complex, multi-component pathway rather than an individual molecule/receptor and should not be directly listed as a canonical therapeutic target. The therapeutic targets within this pathway are specific molecules such as the oxytocin receptor and L-type calcium channels.

Other names

uterine contraction pathwaymyometrial contraction pathwayuterus contractility signaling

Oxytocin: activates PLC via GPCR, increases intracellular Ca²⁺, promotes contraction. Calcium channel blockers: inhibit Ca²⁺ influx, suppress contraction. Beta-adrenergic agonists: increase cAMP, activate relaxation signals. Tocolytics: target various steps to inhibit contractions.